Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study

Advances in Therapy

Volumn 30, Issue 11, 2013, Pages 1007-1017

  Choi, Peter ^a   Farouk, Mourad ^b   Manamley, Nick ^c   Addison, Janet ^c  

^a JOHN HUNTER HOSPITAL   (Australia)

^b AMGEN INC   (United States)

^c AMGEN LTD   (United Kingdom)

Author keywords

Anemia; Chronic kidney disease; Darbepoetin alfa; Dose conversion; Erythropoiesis stimulating agent; Hematology; Hemodialysis; Medication switching; Pegylated erythropoietin beta; Retrospective study

Indexed keywords

HEMOGLOBIN; LONG ACTING DRUG; MACROGOL; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; COHORT ANALYSIS; DOSE CALCULATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDY; MULTICENTER STUDY; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84890125763     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0063-y     Document Type: Article

References (13)

1. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2002;162:1401-8.
2. Kazmi WH, Kausz AT, Khan S, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis. 2001;38:803-12.
3. Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). Kidney Int. 1985;28:1-5.
4. Macdougall IC. Optimizing the use of erythropoietic agents - pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant. 2002;17(Suppl 5):66-70.
5. Macdougall IC. New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis. 2012;59:444-51.
6. Hörl WH. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease. Drugs. 2013;73:117-30.
7. ® (darbepoetin alfa) Summary of product characteristics. Amgen Europe B.V., Breda, The Netherlands, 29 August 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000332/WC500026149.pdf. Accessed 18 October 2013.
8. ® (methoxy polyethylene glycol-epoetin beta) Summary of product characteristics. Roche Registration Ltd., Welwyn Garden City, UK, 19 June 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000739/WC500033672.pdf. Accessed 18 October 2013.
9. Locatelli F, Aljama P, Barany P, et al. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Section III: Treatment of renal anaemia. Nephrol Dial Transplant. 2004;19(Suppl 2):ii16-31.
10. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;327:307-10.
11. Carrera F, Lok CE, de Francisco A, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant. 2010;25:4009-17.
12. Canaud B, Mingardi G, Braun J, et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant. 2008;23:3654-61.
13. Macdougall IC, Obrador GT, El Nahas M. How important is transfusion avoidance in 2013? Nephrol Dial Transplant. 2013;28:1092-9.